Should I Buy LFST? LFST 2026 Analysis

Should You Buy LifeStance Health Group Inc (LFST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

6.700

1 Day change

-1.90%

52 Week Range

8.290

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Good buy right now for an impatient, tactical entry: price is sitting on/just above first support (S1 ~6.945) with short-term oversold conditions, which favors a bounce setup.
Upside skew supported by Wall Street: multiple recent Buy/Outperform ratings with rising targets ($8–$11) versus current ~$6.96.
Main caution: trend momentum is still bearish (MACD worsening) and insider selling has accelerated; this is a buy for a rebound/positioning into catalysts, not a “clean” uptrend chase.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.0574) and negatively expanding → downside momentum still in control.
RSI: RSI(6) at ~27.7 suggests short-term oversold/washed-out conditions, often consistent with near-term rebound attempts.
Moving averages: converging MAs indicate indecision/transition, not a confirmed bullish trend.
Key levels: Pivot ~7.164 is immediate overhead resistance; S1 ~6.945 (price ~6.96 is right on it) and S2 ~6.809 are the next downside levels; R1 ~7.384 then R2 ~7.52 are rebound targets.
Pattern-based projection (similar candlestick analogs): indicates a mild positive drift (≈+0.54% next day, +1.97% next week, +7.32% next month), supportive of a bounce thesis.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put/Call open interest ratio 0.04 (calls dominate) → strongly bullish skew in positioning.
Activity: today’s options volume is extremely low (2 contracts) → sentiment signal is more from OI than fresh flow.
Volatility: 30D IV ~60% vs historical vol ~23.5% and IV percentile ~84 → options are priced rich; market is assigning meaningful move risk into the coming weeks (notably ahead of earnings on 2026-03-05).

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst support strengthening: several Buy/Outperform ratings with recent price target raises.
- Revenue growth: 2025/Q3 revenue +16.34% YoY indicates demand expansion.
- Potential rebound setup: oversold RSI near support often attracts short-term dip buyers.
- Upcoming event: QDEC 2025 earnings on 2026-03-05 (pre-market) can act as a catalyst if guidance/metrics improve.

Neutral/Negative Catalysts

- Insider selling: insiders are selling, and selling increased 132.67% over the last month → negative signal on near-term confidence.
- Momentum still bearish: MACD worsening suggests rallies may face selling pressure.
- Profitability pressure: 2025/Q3 net income down sharply YoY and EPS at 0 → growth isn’t translating cleanly to bottom-line yet.
- No supportive news flow: no recent news catalysts in the last week.

Financial Performance

Latest reported quarter: 2025/Q3
Revenue: $363.81M, +16.34% YoY (clear top-line growth).
Net income: $1.08M, down -118.08% YoY (material deterioration vs prior year).
EPS: 0, down -100% YoY.
Takeaway: growth is solid on revenue, but profitability/earnings quality is currently the weak link heading into the next earnings cycle.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: ratings/targets have been moving up, reinforcing a constructive Wall Street stance.
2026-02-02 (BTIG): Buy, PT raised $10 → $11 (views LFST as a proven operator across cycles).
2026-01-08 (Canaccord): Buy, PT raised $8 → $9 (sees insulation from broader healthcare uncertainty).
2025-12-12 (BTIG): Buy, PT raised $9 → $10 (macro/utilization trends supportive for mental health demand).
2025-11-12 (BMO): Initiated Outperform, PT $8 (upside from productivity + specialty expansion).
2025-11-07 (UBS): Buy, PT raised $9 → $10 (noted Q3 beat and raised FY profit outlook).
Wall Street pros: consistent execution narrative, demand tailwinds, attractive valuation framing.
Wall Street cons: execution risk on productivity/specialty expansion and ongoing profitability sensitivity.

8 Analyst Rating

Wall Street analysts forecast LFST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFST is 9.07 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.830

Low

Averages

9.07

High

Current: 6.830

Low

Averages

9.07

High

BTIG

David Larsen

Buy

maintain

$10 -> $11

AI Analysis

2026-02-02

Reason

BTIG

David Larsen

Price Target

$10 -> $11

AI Analysis

2026-02-02

maintain

Buy

Reason

BTIG analyst David Larsen raised the firm's price target on LifeStance to $11 from $10 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 for Healthcare IT and Digital Health names. The firm is positive on the stock being among proven operators that have been performing consistently well, through many different cycles, the analyst tells investors in a research note.

Canaccord

Richard Close

Buy

maintain

$8 -> $9

2026-01-08

Reason

Canaccord

Richard Close

Price Target

$8 -> $9

2026-01-08

maintain

Buy

Reason

Canaccord analyst Richard Close raised the firm's price target on LifeStance to $9 from $8 and keeps a Buy rating on the shares. The firm updated its model to reflect opportunity amid an uncertain healthcare environment while the company could be insulated from much of the uncertainty in broader healthcare ecosystem, with payers continuing to be supportive of expanding in-network access to care.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LFST

Unlock Now

LFST Should I Buy

LFST Should I Buy

Should You Buy LifeStance Health Group Inc (LFST) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch